Merck, Schering-Plough resolve Vytorin investigation
This article was originally published in The Tan Sheet
Executive Summary
Merck and Schering-Plough will pay $5.4 million to 35 states and the District of Columbia to resolve an investigation into the firms' delayed release of negative study results for the cholesterol-lowering drug Vytorin. The agreement, which is not an admission of liability, covers the states' and D.C.'s investigative costs. The ENHANCE trial found Vytorin was no more effective in reducing plaque in carotid arteries than simvastin (1"The Tan Sheet" Feb. 4, 2008)